Bruce Brockstein to Cetuximab
This is a "connection" page, showing publications Bruce Brockstein has written about Cetuximab.
Connection Strength
0.203
-
Management of recurrent head and neck cancer: recent progress and future directions. Drugs. 2011 Aug 20; 71(12):1551-9.
Score: 0.098
-
The role of inhibitors of the epidermal growth factor in management of head and neck cancer. J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706.
Score: 0.079
-
A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1391-8.
Score: 0.027